High mobility group protein B1 and breast cancer

doi:10.3760/cma.j.cn371439-20200414-00022

Abstract

Abstract:

High mobility group protein B1 (HMGB1) is a kind of nuclear protein widely existing in cells, which is released or secreted from cells by stress in the body and plays a key role in the survival or death pathways of cells. HMGB1 has a huge biological function and is the main regulator of major diseases such as inflammatory diseases and tumors. HMGB1 is closely related to the proliferation, differentiation, migration, apoptosis and drug resistance of tumor cells. With the continuous deepening of research on HMGB1, it is found that HMGB1 plays an important role in the occurrence, development, metastasis and drug resistance of breast cancer. Combined with the research status of HMGB1, the expression of HMGB1 in breast cancer is discussed to provide a new therapeutic scheme for clinical treatment.

Key words: HMGB1 protein, Breast neoplasms, Neoplasm metastasis, Drug resistance,neoplasm

Zhang Yanqiang, Zhang Yang, Li Chunhua, Zhang Dianping, Liu Baoguo, Peng Xiangeng. High mobility group protein B1 and breast cancer[J]. Journal of International Oncology, 2020, 47(5): 297-300.

References 26

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Van Rooijen JM, Qiu SQ, Timmer-Bosscha H, et al. Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer[J]. Eur J Cancer, 2018,103:52-60. DOI: 10.1016/j.ejca.2018.08.001. doi: 10.1016/j.ejca.2018.08.001 pmid: 30208359
[3]	Xu Y, Chen Z, Zhang G, et al. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer[J]. Tumour Biol, 2015,36(11):9039-9047. DOI: 10.1007/s13277-015-3624-7. doi: 10.1007/s13277-015-3624-7 pmid: 26084608
[4]	Reeves R. High mobility group (HMG) proteins: modulators of chromatin structure and DNA repair in mammalian cells[J]. DNA Repair (Amst), 2015,36:122-136. DOI: 10.1016/j.dnarep.2015.09.015. doi: 10.1016/j.dnarep.2015.09.015
[5]	Taniguchi N, Kawakami Y, Maruyama I, et al. HMGB proteins and arthritis[J]. Hum Cell, 2018,31(1):1-9. DOI: 10.1007/s13577-017-0182-x. doi: 10.1007/s13577-017-0182-x pmid: 28916968
[6]	Yang R, Zou X, Tenhunen J, et al. HMGB1 and extracellular histones significantly contribute to systemic inflammation and multiple organ failure in acute liver failure[J]. Mediators Inflamm, 2017,2017:5928078. DOI: 10.1155/2017/5928078. doi: 10.1155/2017/5928078 pmid: 28694564
[7]	张静娇, 邓春青. 与疾病相关的HMGB1基因多态性研究进展[J]. 国际生物医学工程杂志, 2019,42(4):357-361. DOI: 10.3760/cma.j.issn.1673-4181.2019.04.015.
[8]	Yun CW, Lee SH. The roles of autophagy in cancer[J]. Int J Mol Sci, 2018, 19(11). pii: E3466. DOI: 10.3390/ijms19113466.
[9]	Kumai T, Celis E, Rodriguez PC. Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC[J]. J Leukoc Biol, 2016,100(3):447-449. DOI: 10.1189/jlb.3CE0216-091R. doi: 10.1189/jlb.3CE0216-091R pmid: 27587376
[10]	Su Z, Ni P, She P, et al. Bio-HMGB1 from breast cancer contri-butes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells[J]. Cancer Immunol Immunother, 2017,66(3):391-401. DOI: 10.1007/s00262-016-1942-2. doi: 10.1007/s00262-016-1942-2 pmid: 27987020
[11]	Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloid-derived suppressor cells[J]. Oncoimmunology, 2016,5(2):e1004983. DOI: 10.1080/2162402x.2015.1004983. doi: 10.1080/2162402X.2015.1004983 pmid: 27057424
[12]	Wang H, Zou C, Zhao W, et al. Juglone eliminates MDSCs accumulation and enhances antitumor immunity[J]. Int Immunopharmacol, 2019,73:118-127. DOI: 10.1016/j.intimp.2019.04.058. doi: 10.1016/j.intimp.2019.04.058 pmid: 31085459
[13]	Wan W, Cao L, Khanabdali R, et al. The emerging role of HMGB1 in neuropathic pain: a potential therapeutic target for neuroinflammation[J]. J Immunol Res, 2016,2016:6430423. DOI: 10.1155/2016/6430423. doi: 10.1155/2016/6430423 pmid: 27294160
[14]	Bhat AA, Uppada S, Achkar IW, et al. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk[J]. Front Physiol, 2018,9:1942. DOI: 10.3389/fphys.2018.01942. doi: 10.3389/fphys.2018.01942 pmid: 30728783
[15]	Ying S, Xiao X, Chen T, et al. PPAR ligands function as suppressors that target biological actions of HMGB1[J]. PPAR Res, 2016,2016:2612743. DOI: 10.1155/2016/2612743. doi: 10.1155/2016/2612743 pmid: 27563308
[16]	王超群, 黄必飞, 王艳, 等. 乳腺癌中高迁移率族蛋白B1蛋白表达及其临床病理意义[J]. 中华病理学杂志, 2020,49(1):57-61. DOI: 10.3760/cma.j.issn.0529-5807.2020.01.011.
[17]	Sharma AK, Sharma VR, Gupta GK, et al. Advanced glycation end products (AGEs), glutathione and breast cancer: factors, mechanism and therapeutic interventions[J]. Curr Drug Metab, 2019,20(1):65-71. DOI: 10.2174/1389200219666180912104342. doi: 10.2174/1389200219666180912104342 pmid: 30207227
[18]	Xiang L, Semenza GL. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy[J]. Adv Cancer Res, 2019,141:175-212. DOI: 10.1016/bs.acr.2018.11.001. doi: 10.1016/bs.acr.2018.11.001 pmid: 30691683
[19]	Wang F, Sheng JF, Cai L, et al. The telomerase and alternative lengthening of telomeres mechanisms regulate laryngeal cancer cell apoptosis via the PI3K/Akt pathway[J]. ORL J Otorhinolaryngol Relat Spec, 2018,80(5-6):227-237. DOI: 10.1159/000489461. doi: 10.1159/000489461 pmid: 30212832
[20]	Shi Y, Zhang W, Ye Y, et al. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway[J]. Cancer Biol Med, 2018,15(3):314-321. DOI: 10.20892/j.issn.2095-3941.2017.0188. doi: 10.20892/j.issn.2095-3941.2017.0188 pmid: 30197799
[21]	Choi AH, O'leary MP, Lu J, et al. Endogenous Akt activity promotes virus entry and predicts efficacy of novel chimeric orthopoxvi-rus in triple-negative breast cancer[J]. Mol Ther Oncolytics, 2018,9:22-29. DOI: 10.1016/j.omto.2018.04.001. doi: 10.1016/j.omto.2018.04.001 pmid: 29988465
[22]	Sharifi S, Barar J, Hejazi MS, et al. Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells[J]. Adv Pharm Bull, 2015,5(3):351-359. DOI: 10.15171/apb.2015.049. doi: 10.15171/apb.2015.049 pmid: 26504757
[23]	Xu T, Jiang L, Wang Z. The progression of HMGB1-induced autophagy in cancer biology[J]. Onco Targets Ther, 2019,12:365-377. DOI: 10.2147/ott.S185876. doi: 10.2147/OTT.S185876 pmid: 30643434
[24]	Wang N, Yang B, Muhetaer G, et al. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy[J]. Biomed Pharmacother, 2019,120:109519. DOI: 10.1016/j.biopha.2019.109519. doi: 10.1016/j.biopha.2019.109519 pmid: 31629951
[25]	Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction[J]. Pharmacol Ther, 2017,172:34-49. DOI: 10.1016/j.pharmthera.2016.11.012. doi: 10.1016/j.pharmthera.2016.11.012 pmid: 27916656
[26]	Sun Q, Liu T, Yuan Y, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1[J]. Int J Cancer, 2015,136(5):1003-1012. DOI: 10.1002/ijc.29065. doi: 10.1002/ijc.29065 pmid: 25044403